Oleclumab

Drug Profile

Oleclumab

Alternative Names: Anti-CD73 MAb; Anti-CD73 monoclonal antibody; MEDI 9447

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 24 Jul 2015 MedImmune plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT02503774)
  • 01 Jul 2015 Phase-I clinical trials in Solid tumours (Combination therapy, Monotherapy) in USA (unspecified route)
  • 19 Apr 2015 Preclinical trials in Solid tumours in USA (unspecified route) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top